|
19.9.2022 |
EN |
Official Journal of the European Union |
C 359/68 |
Judgment of the General Court of 13 July 2022 — Purasac v EUIPO — Prollenium Medical Technologies (Rejeunesse)
(Case T-543/21) (1)
(EU trade mark - Opposition proceedings - Application for the EU figurative mark Rejeunesse - Earlier EU word mark REVANESSE - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)
(2022/C 359/83)
Language of the case: English
Parties
Applicant: Purasac Co. Ltd (Anyang-si, South Korea) (represented by: P. Lee, lawyer)
Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska and J. Crespo Carrillo, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Prollenium Medical Technologies, Inc. (Aurora, Ontario, Canada) (represented by: R. Lyxell, lawyer)
Re:
By its action brought under Article 263 TFEU, the applicant seeks annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 2 July 2021 (Case R 146/2021-4).
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Purasac Co. Ltd to pay the costs. |